Close Menu

Centogene: Sun Kim, Oved Amitay

May 15, 2020

Sun Kim will become interim chief business officer of Centogene, effective June 1. He will replace Oved Amitay, who will leave the company on May 31, until a permanent chief business officer has been appointed. Kim is currently Centogene's chief strategy and investor relations officer. Prior to that, he was head of corporate strategy at Shire, and before that, he held multiple roles in the Alcon division of Novartis. Kim holds PhD and MS degrees in chemical engineering from Stanford University.

More Like This

Jul 02, 2020

Berkeley Lights: Greg Lucier

Greg Lucier has joined the board of directors of Berkeley Lights. He is the CEO of Corza Health and previously served as CEO of Nuvasive, where he remains chairman, and as chairman and CEO of Life Technologies. Prior to that, he held executive roles with General Electric. Lucier holds an MBA from Harvard Business School and a BS in industrial engineering from Pennsylvania State University.

Jun 29, 2020

Cergentis: Joris Schuurmans, Dirk Pollet, Maja Sanders

Cergentis of Utrecht, the Netherlands, this week announced a number of new appointments. Joris Schuurmans has become the firm's CEO, replacing Jan Dekker. Schuurmans joins Cergentis from Skyline Dx, where he led the melanoma program. Previously, he held senior executive positions at Biocartis and at MyCartis.

Further, Dirk Pollet and Maja Sanders have joined the company's supervisory board. Pollet is CEO of Enzyre and is the former CEO of Multiplicom, which was acquired by Agilent Technologies. Sanders holds supervisory roles at various organizations and has managerial experience in the private equity industry.

Jun 27, 2020

IsoPlexis: Peter Siesel

IsoPlexis has appointed Peter Siesel as chief commercial officer. Siesel joins IsoPlexis from Tecan, where he most recently served as senior vice president of sales and was responsible for commercialization in the Americas.

Jun 23, 2020

NeoGenomics: Cynthia Dieter

NeoGenomics announced the appointment of Cynthia Dieter as chief accounting officer and controller, effective June 22. Before coming to NeoGenomics, Dieter was the senior director of corporate accounting at Viasat. She has also served in multiple roles at DJO Global, including VP and assistant corporate controller, VP and vista controller, and director of financial reporting and planning. 

In addition, Dieter has been the manager of financial reporting at Captiva Software and audit manager for Ernst and Young. 

Jun 19, 2020

Guardant Health: Vijaya Gadde

Guardant Health has appointed Vijaya Gadde to serve on its Board of Directors. Gadde is Twitter's chief legal officer leading its legal, public policy, and trust and safety teams globally. Prior to joining Twitter in 2011, she was senior director, legal at Juniper Networks. Before that, she worked for nearly a decade at Wilson Sonsini Goodrich & Rosati. Gadde serves on the Board of Trustees of NYU Law School and the Board of Directors of Mercy Corps. She is also a co-founder of #Angels, an investment collective focused on funding diverse and ambitious founders pursuing bold ideas. She earned a JD from New York University School of Law and a BS in industrial and labor relations from Cornell University.

Jun 18, 2020

T2 Biosystems: Thierry Bernard, Ninfa Saunders, Robin Toft

T2 Biosystems has appointed Thierry Bernard, Ninfa Saunders, and Robin Toft to its board of directors. Bernard currently serves as CEO of Qiagen, Saunders is president and CEO of Navicent Health, and Toft is founder and CEO of Toft Group and previously served as senior vice president of commercial operations at Roche Molecular Diagnostics. T2 Biosystems also announced that Michael CimaAdrian Jones, and Stanley Lapidus will be leaving the firm's board of directors.

Jun 18, 2020

Waters: Christopher O'Connell

Christopher O'Connell will step down as president, CEO, and a member of the board of directors of Waters, the firm announced this week. Waters said that it has hired an executive search firm to identify a new CEO and that O'Connell will serve as an advisor until the end of this year to support the transition. O'Connell has served as president and CEO of Waters for the past five years, succeeding the firm's long-time leader Doug Berthiaume. According to terms of O'Connell's separation agreement, he will receive a cash severance in the amount of $4,252,500, payable over a two-year period following termination of employment and a bonus for calendar year 2020 based on the company's performance.

Jun 17, 2020

IonPath: Brad Nelson

IonPath has appointed Brad Nelson as senior vice president of marketing and corporate strategy. Nelson will lead marketing, product management, and application functions related to the company's multiplexed ion beam Imaging technology. Nelson most recently served as VP of marketing at Magnolia Medical Technologies. Prior to that he was head of marketing and director of corporate development at Labcyte (now part of Danaher). He also previously led marketing efforts at Velocity11, which was acquired by Agilent.

Jun 17, 2020

Phase Genomics: Kayla Young

Phase Genomics, a University of Washington spinout providing proximity-ligation next-generation sequencing solutions for metagenome assembly, has appointed Kayla Young as its chief operating officer. Young joined Phase Genomics in 2017 as director of operations. She also has previous experience at Life Science Washington, and received a PhD in molecular physiology and biophysics from Vanderbilt University in 2016.

Jun 15, 2020

Laboratory for Advanced Medicine: Samuel Tong

Laboratory for Advanced Medicine has appointed Samuel Tong as CEO for its operations in China. He joins the company from medical research organization NAMSA where he was vice president and general manager of the Asia-Pacific region. Prior to that, he was VP and GM for greater China at Qiagen. Tong was also business unit director of diagnostics systems for greater China at Becton Dickinson, and country manager of China at Abbott Vascular.

Jun 15, 2020

Foundation Medicine: Geoffrey Oxnard

Roche subsidiary Foundation Medicine announced Geoffrey Oxnard has been appointed vice president, global medical lead for the firm's liquid biopsy portfolio, effective immediately. In the role, he'll define research and a liquid biopsy-focused discovery roadmap while investigating novel applications of liquid biopsy approaches to improve cancer research and care.

Oxnard previously served as a thoracic oncologist and clinical investigator at the Dana-Farber Cancer Institute at Harvard Medical School, and he'll continue seeing patients part-time at the institute. His recent research has focused on the clinical application of liquid biopsy technologies to understand drug resistance for selecting targeted therapies and detecting occult cancer. 

Jun 12, 2020

Scipher Medicine: Jerry Conway

Scipher Medicine has named Jerry Conway as senior vice president of market access. He will focus on patient access to Scipher's precision diagnostic tools beginning with PrismRA, a molecular signature test that predicts non-response to anti-TNFs for patients with rheumatoid arthritis, and is slated to launch later this year. Conway most recently served as executive vice president at CDx Diagnostics.

Jun 12, 2020

AACC: Mark Golden

Mark Golden has been appointed the CEO of the American Association for Clinical Chemistry, effective Aug. 17. Prior to joining AACC, he was executive director and CEO of the National Society of Professional Engineers for seven years. AACC had previously said that its current CEO Janet Kreizman would retire from the organization.

Jun 11, 2020

Quidel: Jack Schuler

Jack Schuler has retired from Quidel's board, effective June 10, the firm said. Schuler, 79, has been on Quidel's board since February 2006. He was the former president and chief operating officer of Abbott Laboratories.

Jun 10, 2020

Pacific Biosciences: Michael Hunkapiller, Susan Barnes

Pacific Biosciences announced that CEO and President Michael Hunkapiller will retire by the end of the year. He plans to remain on the company's board. Hunkapiller served eight years as CEO and oversaw the launch of the Sequel and Sequel II instruments.

Susan Barnes, the firm's CFO and executive VP, will also retire in August after more than a decade with the company.

PacBio said it has already begun searching for their replacements.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.